| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary target of K6PC-5 is sphingosine kinase 1 (SphK1 or SK1), an enzyme that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). S1P is a bioactive lipid that regulates various cellular processes including cell proliferation, survival, migration, and angiogenesis through activation of S1P receptors. K6PC-5 acts as a selective and direct activator of SphK1, increasing S1P production. This activation leads to a rapid transient increase in intracellular calcium and promotes keratinocyte differentiation and proliferation.
|
|---|---|
| ln Vitro |
K6PC-5 (1-10 μM; 24 hours) dose-dependently raises the levels of loricin and involucrin in normal human emergency response (NHEK) cells. K6PC-5 uses intracellular Ca2+ nutritional signaling to encourage the creation of new cells. Furthermore, c-Jun N-terminated division phosphorylation and p42/44 extracellular signal regulation are stimulated by K6PC-5 [1]. K6PC-5 (1–10 μM; 24 h) stimulates human fibroblasts and causes oscillations in the intracellular Ca2+ concentration ([Ca2+]i) in these cells [2]. In EA.hy926 cells infected with EBOV, K6PC-5 (10, 25, and 50 μM; 48 hours) dramatically decreased EBOV-induced infection. In cell supernatants, K6PC-5 dramatically lowers viral titers and, in a concentrated way, greatly lowers VP40 levels [3].]
In vitro, K6PC-5 is a selective and direct SphK1 activator that increases S1P production. It elicits a rapid transient increase in intracellular calcium levels and promotes keratinocyte differentiation and proliferation through intracellular Ca²⁺ signaling. The compound also increases keratin 1 and involucrin expression in normal human epidermal keratinocytes cultured in vitro. These effects are consistent with its role in promoting epidermal differentiation and barrier function. |
| ln Vivo |
In an inherently aged hairless mouse (56 weeks old), 1% K6PC-5 was topically administered for 2 weeks. This K6PC-5 therapy greatly enhanced the number of cutaneous fibroblasts and collagen synthesis. Therefore, dermal thickness is also greatly raised in
In vivo, K6PC-5 induces anti-aging effects in intrinsically aged skin and ameliorates intestinal homeostasis in an animal model of Huntington's disease. By activating SphK1 and increasing S1P production, the compound modulates sphingolipid signaling pathways that regulate cell survival, proliferation, and inflammation. Its ability to promote keratinocyte differentiation suggests potential applications in skin aging and wound healing. However, specific in vivo dosing and efficacy data is not detailed in the available sources. |
| Enzyme Assay |
For SphK1 activators, standard cell-free assays involve measuring the kinase activity of recombinant SphK1 using sphingosine and ATP as substrates. The compound is incubated with the enzyme and substrates, and the formation of S1P is measured by LC-MS or radiolabeled methods.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Normal human epidermal keratinocytes (NHEK) Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Involucrin and loricin levels increased in a dose-dependent manner. Cell proliferation experiment [2] Cell Types: human fibroblasts Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 h Experimental Results: Dramatically promoted human fibroblast proliferation and procollagen production. For SphK1 activators, standard cellular assays involve treatment of cells (e.g., keratinocytes, fibroblasts) with the test compound for 1-24 hours. S1P levels in cell lysates or culture medium are measured by LC-MS. Intracellular calcium levels are measured using fluorescent dyes (e.g., Fura-2, Fluo-4). Keratinocyte differentiation markers (keratin 1, involucrin) and proliferation are assessed. |
| Animal Protocol |
Animal/Disease Models: Intrinsically aged hairless mice (56 weeks old) [2]
Doses: 1% (Vehicle (PEG:EtOH = 7:3)) Route of Administration: Topical application; [2 ]. twice (two times) daily for 2 weeks Experimental Results: Enhanced fibroblast proliferation, collagen production, and ultimately increased dermal thickness. For in vivo evaluation of SphK1 activators, standard animal models include models of skin aging, wound healing, and inflammatory diseases. The compound is typically administered topically or systemically, and skin barrier function, wound closure, inflammation markers, and tissue S1P levels are assessed. |
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for K6PC-5 is not extensively provided in the available sources. The compound has a molecular weight of 343.5 and formula C₁₉H₃₇NO₄. It has a purity of 98.55%. As a ceramide derivative with moderate lipophilicity, it would be expected to have reasonable cell permeability and skin penetration. Comprehensive PK studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for K6PC-5 is not provided in the available sources. As a research compound targeting SphK1, standard preclinical toxicology would be required for therapeutic development. The compound's effects on S1P signaling, which regulates diverse physiological processes, would need to be carefully evaluated. The compound is for research use only and not for therapeutic applications.
|
| References |
|
| Additional Infomation |
K6PC-5 is a synthetic ceramide derivative and a selective and direct SphK1 activator. It increases S1P production and elicits a rapid transient increase in intracellular calcium. The compound induces anti-aging effects in intrinsically aged skin and ameliorates intestinal homeostasis in an animal model of Huntington's disease. No regulatory approval has been identified.
|
| Molecular Formula |
C19H37NO4
|
|---|---|
| Molecular Weight |
343.508
|
| Exact Mass |
343.272
|
| CAS # |
756875-51-1
|
| PubChem CID |
11660192
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.812
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
24
|
| Complexity |
329
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CGYVFCHCRBGGJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H37NO4/c1-3-5-7-9-11-13-18(23)17(12-10-8-6-4-2)19(24)20-16(14-21)15-22/h16-17,21-22H,3-15H2,1-2H3,(H,20,24)
|
| Chemical Name |
N-(1,3-dihydroxypropan-2-yl)-2-hexyl-3-oxodecanamide
|
| Synonyms |
K6PC5 K6PC 5 K6PC-5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~291.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9111 mL | 14.5556 mL | 29.1112 mL | |
| 5 mM | 0.5822 mL | 2.9111 mL | 5.8222 mL | |
| 10 mM | 0.2911 mL | 1.4556 mL | 2.9111 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
